JAK2 and essential thrombocythemia: The most frequent mutation is a point mutation in the Janus kinase 2 gene (JAK2) V617F [8] that was recognized in 2005 and is nowadays part of a routine molecular genetic testing in patients with suspected ET [9,10,11,12,13].